These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

693 related articles for article (PubMed ID: 11464240)

  • 21. High frequency of BRCA1/2 germline mutations in 42 Belgian families with a small number of symptomatic subjects.
    Goelen G; Teugels E; Bonduelle M; Neyns B; De Grève J
    J Med Genet; 1999 Apr; 36(4):304-8. PubMed ID: 10227398
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation.
    Meijers-Heijboer H; Brekelmans CT; Menke-Pluymers M; Seynaeve C; Baalbergen A; Burger C; Crepin E; van den Ouweland AW; van Geel B; Klijn JG
    J Clin Oncol; 2003 May; 21(9):1675-81. PubMed ID: 12721241
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term psychological impact of carrying a BRCA1/2 mutation and prophylactic surgery: a 5-year follow-up study.
    van Oostrom I; Meijers-Heijboer H; Lodder LN; Duivenvoorden HJ; van Gool AR; Seynaeve C; van der Meer CA; Klijn JG; van Geel BN; Burger CW; Wladimiroff JW; Tibben A
    J Clin Oncol; 2003 Oct; 21(20):3867-74. PubMed ID: 14551306
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families.
    Kauff ND; Mitra N; Robson ME; Hurley KE; Chuai S; Goldfrank D; Wadsworth E; Lee J; Cigler T; Borgen PI; Norton L; Barakat RR; Offit K
    J Natl Cancer Inst; 2005 Sep; 97(18):1382-4. PubMed ID: 16174860
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of individuals opting for BRCA1/2 or HNPCC genetic susceptibility testing with regard to coping, illness perceptions, illness experiences, family system characteristics and hereditary cancer distress.
    van Oostrom I; Meijers-Heijboer H; Duivenvoorden HJ; Bröcker-Vriends AH; van Asperen CJ; Sijmons RH; Seynaeve C; Van Gool AR; Klijn JG; Tibben A
    Patient Educ Couns; 2007 Jan; 65(1):58-68. PubMed ID: 16872788
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
    Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
    J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Accommodating risk: responses to BRCA1/2 genetic testing of women who have had cancer.
    Hallowell N; Foster C; Eeles R; Ardern-Jones A; Watson M
    Soc Sci Med; 2004 Aug; 59(3):553-65. PubMed ID: 15144764
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mutational analysis of the BRCA1-interacting genes ZNF350/ZBRK1 and BRIP1/BACH1 among BRCA1 and BRCA2-negative probands from breast-ovarian cancer families and among early-onset breast cancer cases and reference individuals.
    Rutter JL; Smith AM; Dávila MR; Sigurdson AJ; Giusti RM; Pineda MA; Doody MM; Tucker MA; Greene MH; Zhang J; Struewing JP
    Hum Mutat; 2003 Aug; 22(2):121-8. PubMed ID: 12872252
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical characteristics affect the impact of an uninformative DNA test result: the course of worry and distress experienced by women who apply for genetic testing for breast cancer.
    van Dijk S; Timmermans DR; Meijers-Heijboer H; Tibben A; van Asperen CJ; Otten W
    J Clin Oncol; 2006 Aug; 24(22):3672-7. PubMed ID: 16877736
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of the I1307K APC mutation with hereditary and sporadic breast/ovarian cancer: more questions than answers.
    Gershoni-Baruch R; Patael Y; Dagan ; Figer A; Kasinetz L; Kadouri E; Bruchim Bar Sade R; Friedman E
    Br J Cancer; 2000 Jul; 83(2):153-5. PubMed ID: 10901363
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interest in genetic testing among first-degree relatives of breast cancer patients.
    Lerman C; Seay J; Balshem A; Audrain J
    Am J Med Genet; 1995 Jul; 57(3):385-92. PubMed ID: 7677139
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Application of BRCA1 and BRCA2 mutation carrier prediction models in breast and/or ovarian cancer families of French Canadian descent.
    Oros KK; Ghadirian P; Maugard CM; Perret C; Paredes Y; Mes-Masson AM; Foulkes WD; Provencher D; Tonin PN
    Clin Genet; 2006 Oct; 70(4):320-9. PubMed ID: 16965326
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anticipated uptake and impact of genetic testing in hereditary breast and ovarian cancer families.
    Struewing JP; Lerman C; Kase RG; Giambarresi TR; Tucker MA
    Cancer Epidemiol Biomarkers Prev; 1995 Mar; 4(2):169-73. PubMed ID: 7742725
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Psychological adjustment among male partners in response to women's breast/ovarian cancer risk: a theoretical review of the literature.
    Sherman KA; Kasparian NA; Mireskandari S
    Psychooncology; 2010 Jan; 19(1):1-11. PubMed ID: 19472298
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Utilization of BRCA1/BRCA2 mutation testing in newly diagnosed breast cancer patients.
    Schwartz MD; Lerman C; Brogan B; Peshkin BN; Isaacs C; DeMarco T; Halbert CH; Pennanen M; Finch C
    Cancer Epidemiol Biomarkers Prev; 2005 Apr; 14(4):1003-7. PubMed ID: 15824179
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analysis of breast cancer susceptibility genes BRCA1 and BRCA2 in Thai familial and isolated early-onset breast and ovarian cancer.
    Patmasiriwat P; Bhothisuwan K; Sinilnikova OM; Chopin S; Methakijvaroon S; Badzioch M; Padungsutt P; Vattanaviboon P; Vattanasapt V; Szabo C; Saunders GF; Goldgar D; Lenoir GM
    Hum Mutat; 2002 Sep; 20(3):230. PubMed ID: 12203997
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel germline BRCA1 and BRCA2 mutations in Turkish women with breast and/or ovarian cancer and their relatives.
    Egeli U; Cecener G; Tunca B; Tasdelen I
    Cancer Invest; 2006; 24(5):484-91. PubMed ID: 16939956
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differences between women who pursued genetic testing for hereditary breast and ovarian cancer and their at-risk relatives who did not.
    Katapodi MC; Northouse L; Pierce P; Milliron KJ; Liu G; Merajver SD
    Oncol Nurs Forum; 2011 Sep; 38(5):572-81. PubMed ID: 21875844
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer.
    Hamel N; Kotar K; Foulkes WD
    BMC Med Genet; 2003 Aug; 4():7. PubMed ID: 12911837
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Genetic test and prophylactic treatment in breast cancer families].
    Miyoshi Y; Noguchi S
    Gan To Kagaku Ryoho; 2002 Apr; 29(4):512-22. PubMed ID: 11977534
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.